Notes
Surveillance, Epidemiology, and End Results Program
incremental cost effectiveness ratio
Reference
Webber-Foster R, et al. Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand. PharmacoEconomics : 24 May 2014. Available from: URL: http://doi.org/10.1007/s40273-014-0154-x
Rights and permissions
About this article
Cite this article
Docetaxel abreast of paclitaxel in New Zealand, or not?. PharmacoEcon Outcomes News 704, 4 (2014). https://doi.org/10.1007/s40274-014-1282-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1282-4